Neoadjuvant Chemotherapy: Not the Best Option in Estrogen Receptor-Positive, HER2-Negative, Invasive Classical Lobular Carcinoma of the Breast?

Arnie Purushotham; Sarah Pinder; Massi Cariati; Mark Harries; Aron Goldhirsch

doi:10.1200/JCO.2009.27.8184

Neoadjuvant Chemotherapy: Not the Best Option in Estrogen Receptor-Positive, HER2-Negative, Invasive Classical Lobular Carcinoma of the Breast?

Arnie Purushotham, Sarah Pinder, Massi Cariati, Mark Harries, Aron Goldhirsch

Comprehensive Cancer Centre

Research output: Contribution to journal › Editorial › peer-review

40 Citations (Scopus)

Original language	English
Pages (from-to)	3552 - 3554
Number of pages	3
Journal	Journal of Clinical Oncology
Volume	28
Issue number	22
DOIs	https://doi.org/10.1200/JCO.2009.27.8184
Publication status	Published - 1 Aug 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2009.27.8184

Cite this

@article{d19c413c1edf4f52b6b4d2c0da0886ae,

title = "Neoadjuvant Chemotherapy: Not the Best Option in Estrogen Receptor-Positive, HER2-Negative, Invasive Classical Lobular Carcinoma of the Breast?",

author = "Arnie Purushotham and Sarah Pinder and Massi Cariati and Mark Harries and Aron Goldhirsch",

year = "2010",

month = aug,

day = "1",

doi = "10.1200/JCO.2009.27.8184",

language = "English",

volume = "28",

pages = "3552 -- 3554",

journal = "Journal of Clinical Oncology",

issn = "1527-7755",

publisher = "American Society of Clinical Oncology",

number = "22",

}

TY - JOUR

T1 - Neoadjuvant Chemotherapy

T2 - Not the Best Option in Estrogen Receptor-Positive, HER2-Negative, Invasive Classical Lobular Carcinoma of the Breast?

AU - Purushotham, Arnie

AU - Pinder, Sarah

AU - Cariati, Massi

AU - Harries, Mark

AU - Goldhirsch, Aron

PY - 2010/8/1

Y1 - 2010/8/1

U2 - 10.1200/JCO.2009.27.8184

DO - 10.1200/JCO.2009.27.8184

M3 - Editorial

SN - 1527-7755

VL - 28

SP - 3552

EP - 3554

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 22

ER -